Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18878740 | 0.91 | MAOB (0.42) | MAOBFFAR1FFAR4NR4A2MAPT | |
| SCHEMBL16527546 | 0.88 | ICAM1 (0.39) | MAOBMAPTL3MBTL1S1PR1 | |
| SCHEMBL16590249 | 0.87 | S1PR1 (0.48) | MAOBFFAR1MAPTL3MBTL1MAOA | |
| Hydrochloric Acid SCHEMBL16527322 | 0.86 | S1PR1 (0.48) | MAOBFFAR1MAPTL3MBTL1MAOA | |
| SCHEMBL16590051 | 0.83 | ICAM1 (0.37) | MAOBMAPTL3MBTL1S1PR1 | |
| SCHEMBL16527365 | 0.83 | CACNA1B (0.38) | MAOBS1PR1 | |
| SCHEMBL16590237 | 0.83 | S1PR1 (0.47) | MAOBFFAR1MAPTL3MBTL1MAOA | |
| SCHEMBL16527368 | 0.83 | S1PR1 (0.47) | MAOBFFAR1MAPTL3MBTL1MAOA | |
| SCHEMBL16590040 | 0.82 | S1PR1 (0.39) | S1PR1 | |
| SCHEMBL16590170 | 0.81 | S1PR1 (0.39) | MAPTS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657043-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9657043-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20150087620-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-26 | — | — | US | disclosed |
| US-20150087620-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087620-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | HLA-B, HLA-A, HLA-C | MAOB 58/4885FFAR1 2226/4885FFAR4 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.